Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
Authors:
Open Access
- 31 August 2017
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 50 (2) , 1700918
Abstract
Uptake of Xpert in 22 high burden countries has progressed well since 2014, although more can be done to reach scale http://ow.ly/Whvu30dpqVIKeywords
Funding Information
- Foundation For Innovative New Diagnostics
This publication has 8 references indexed in Scilit:
- Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?European Respiratory Journal, 2017
- Tuberculosis innovations mean little if they cannot save liveseLife, 2017
- Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert ® MTB/RIF in ZimbabwePublic Health Action, 2016
- Xpert® MTB/RIF for smear-negative presumptive TB: impact on case notification in DR CongoThe International Journal of Tuberculosis and Lung Disease, 2016
- How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries?European Respiratory Journal, 2014
- Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential?European Respiratory Journal, 2014
- Results from early programmatic implementation of Xpert MTB/RIF testing in nine countriesBMC Infectious Diseases, 2014
- From Where Are Tuberculosis Patients Accessing Treatment in India? Results from a Cross-Sectional Community Based Survey of 30 DistrictsPLOS ONE, 2011